News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
581,399 Results
Type
Article (19336)
Company Profile (166)
Press Release (561896)
Multimedia
Podcasts (82)
Webinars (13)
Section
Business (198816)
Career Advice (708)
Deals (30797)
Drug Delivery (90)
Drug Development (65969)
Employer Resources (54)
FDA (12463)
Job Trends (11116)
News (288708)
Policy (24258)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Genetown Elite (1)
2027 Genetown Standard (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (825)
Accelerated approval (43)
ADA (29)
Adcomms (10)
Allergies (140)
Alliances (41982)
ALS (142)
Alzheimer's disease (1267)
Antibody-drug conjugate (ADC) (350)
Approvals (13073)
Artificial intelligence (506)
ASCO (220)
Autoimmune disease (249)
Automation (40)
Bankruptcy (319)
Best Places to Work (8375)
BIO (47)
BIOSECURE Act (10)
Biosimilars (199)
BioSpace Insights (77)
Biotechnology (103)
Bladder cancer (153)
Brain cancer (55)
Breast cancer (599)
Cancer (4469)
Cardiovascular disease (348)
Career advice (610)
Career pathing (14)
CAR-T (218)
CDC (8)
Celiac Disease (1)
Cell therapy (611)
Cervical cancer (41)
Clinical research (59083)
Collaboration (1721)
Commercialization (3)
Company closure (1)
Compensation (1425)
Complete response letters (61)
COVID-19 (1283)
CRISPR (82)
C-suite (1028)
Cystic fibrosis (125)
Data (6563)
Decentralized trials (1)
Denatured (23)
Depression (126)
Dermatology (67)
Diabetes (439)
Diagnostics (4812)
Digital health (45)
Diversity (3)
Diversity, equity & inclusion (16)
Drug discovery (261)
Drug pricing (140)
Drug shortages (15)
Duchenne muscular dystrophy (227)
Earnings (80888)
Editorial (25)
Employer branding (5)
Employer resources (50)
Events (99256)
Executive appointments (949)
FDA (15573)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (19)
Frontotemporal dementia (27)
Funding (1218)
Gene editing (163)
Generative AI (35)
Gene therapy (458)
GLP-1 (700)
Government (2032)
Grass and pollen (5)
Guidances (331)
Healthcare (11057)
Hematology (128)
HIV (55)
Huntington's disease (28)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (96)
Immunology and inflammation (174)
Immuno-oncology (76)
Indications (194)
Infectious disease (1515)
Inflammatory bowel disease (174)
Inflation Reduction Act (10)
Influenza (98)
Intellectual property (290)
Interviews (96)
IPO (13990)
IRA (39)
Job creations (3114)
Job search strategy (553)
JPM (29)
Kidney cancer (20)
Labor market (40)
Layoffs (257)
Leadership (11)
Legal (6604)
Licensing (3)
Liver cancer (55)
Longevity (21)
Lung cancer (646)
Lymphoma (339)
Machine learning (35)
Management (18)
Manufacturing (890)
Marketing (11)
MASH (168)
Medical affairs (1)
Medical device (9251)
Medtech (9389)
Mergers & acquisitions (17950)
Metabolic disorders (1082)
mRNA (109)
Multiple sclerosis (139)
NASH (17)
Neurodegenerative disease (294)
Neuropsychiatric disorders (71)
Neuroscience (2410)
Neurotech (1)
NextGen: Class of 2026 (3906)
Non-profit (1262)
Now hiring (23)
Obesity (446)
Opinion (163)
Ovarian cancer (174)
Pain (242)
Pancreatic cancer (221)
Parkinson's disease (272)
Partnered (20)
Patents (568)
Patient recruitment (580)
Peanut (39)
People (50695)
Pharmaceutical (45)
Pharmacy benefit managers (24)
Phase 1 (18187)
Phase 2 (25927)
Phase 3 (19295)
Pipeline (8180)
Policy (176)
Postmarket research (2188)
Preclinical (7545)
Press Release (49)
Prostate cancer (233)
Psychedelics (30)
Radiopharmaceuticals (267)
Rare diseases (843)
Real estate (4473)
Recruiting (20)
Regulatory (19742)
Reports (23)
Research institute (962)
Resumes & cover letters (95)
Rett syndrome (40)
RNA editing (12)
RSV (52)
Schizophrenia (147)
Series A (223)
Series B (155)
Service/supplier (4)
Sickle cell disease (97)
Special edition (12)
Spinal muscular atrophy (112)
Sponsored (15)
Startups (2794)
State (2)
Stomach cancer (8)
Supply chain (96)
Tariffs (71)
The Weekly (57)
Vaccines (510)
Venture capital (56)
Weight loss (243)
Women's health (97)
Worklife (4)
Date
Today (10)
Last 7 days (430)
Last 30 days (1464)
Last 365 days (23198)
2026 (13673)
2025 (23392)
2024 (27333)
2023 (31445)
2022 (40841)
2021 (43452)
2020 (39935)
2019 (29788)
2018 (22684)
2017 (24799)
2016 (23606)
2015 (29522)
2014 (25739)
2013 (22158)
2012 (24165)
2011 (24477)
2010 (23718)
Location
Africa (473)
Alabama (80)
Alaska (2)
Arizona (321)
Arkansas (13)
Asia (30185)
Australia (4157)
California (12309)
Canada (3373)
China (1017)
Colorado (494)
Connecticut (464)
Delaware (269)
Europe (55453)
Florida (1878)
Georgia (395)
Hawaii (3)
Idaho (49)
Illinois (845)
India (90)
Indiana (546)
Iowa (14)
Japan (551)
Kansas (117)
Kentucky (36)
Louisiana (29)
Maine (27)
Maryland (1324)
Massachusetts (8484)
Michigan (317)
Minnesota (589)
Mississippi (5)
Missouri (103)
Montana (27)
Nebraska (16)
Nevada (114)
New Hampshire (68)
New Jersey (3114)
New Mexico (18)
New York (3039)
North Carolina (1478)
North Dakota (4)
Northern California (6143)
Ohio (294)
Oklahoma (17)
Oregon (28)
Pennsylvania (2357)
Puerto Rico (26)
Rhode Island (36)
South America (737)
South Carolina (78)
South Dakota (1)
Southern California (5061)
Tennessee (140)
Texas (1965)
United States (41788)
Utah (376)
Vermont (1)
Virginia (257)
Washington D.C. (52)
Washington State (961)
West Virginia (2)
Wisconsin (102)
Wyoming (1)
581,399 Results for "boehringer ingelheim pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies
· New research team expands capabilities at Boehringer’s U.S. R&D site in Ridgefield, Connecticut.
July 9, 2026
·
1 min read
Policy
Germany rethinking drug price reforms after Lilly, Boehringer withdraw investments:
Reuters
Weeks after Boehringer Ingelheim and Eli Lilly retracted billions of dollar in German commitments, the nation’s government is reportedly changing a contentious element of its planned healthcare reforms.
June 15, 2026
·
2 min read
·
Nick Paul Taylor
Obesity
ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reduction
While survodutide’s 16.6% overall weight loss was underwhelming, Boehringer Ingelheim and Zealand Pharma’s drug achieved “impressive” fat loss, according to BMO Capital Markets.
June 8, 2026
·
2 min read
·
Tristan Manalac
Manufacturing
Lilly and Boehringer roll back billions in German investments over health budget cuts
With Germany moving to curb healthcare spending, Eli Lilly and Boehringer Ingelheim have rethought plans to invest in facilities, including a manufacturing plant for GLP-1 drugs.
June 4, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
Guardant Health Announces FDA Approval of Guardant360 CDx as Companion Diagnostic for Boehringer Ingelheim’s HERNEXEOS®
June 11, 2026
·
5 min read
Press Releases
Boehringer Ingelheim’s oncology portfolio shows strong promise across multiple cancers at ASCO 2026
May 22, 2026
·
14 min read
Press Releases
Boehringer Ingelheim strengthens obesity pipeline as potential first-in-class triple receptor agonist BI 3034701 enters Phase II development
July 16, 2026
·
6 min read
Press Releases
Boehringer Ingelheim reports first-half 2026 sales growth, driven by JARDIANCE® and new product launches in the U.S.
July 15, 2026
·
5 min read
Obesity
Boehringer, Zealand’s obesity drug ‘more akin’ to Novo’s Wegovy in Phase 3
Topline Phase 3 results of survodutide—licensed to Boehringer Ingelheim from Zealand Pharma—are more comparable to Novo Nordisk’s Wegovy than to Eli Lilly’s Zepbound, William Blair analysts said on Tuesday.
April 28, 2026
·
2 min read
·
Heather McKenzie
Press Releases
Boehringer Ingelheim accelerates precision oncology research with initiation of three Phase III trials in hard-to-treat cancers
June 22, 2026
·
9 min read
1 of 58,140
Next
